Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

COVE-2: A Phase 3, Double-blind, Randomized, Vehicle-controlled Study to Evaluate the Efficacy and Safety of YCANTH (VP-102) in Subjects With Common Warts (Verruca Vulgaris)

NCT07246590 is registered in ClinicalTrials.gov with Verrica Pharmaceuticals Inc. as lead sponsor.

NCT NCT07246590
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07246590 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
COVE-2: A Phase 3, Double-blind, Randomized, Vehicle-controlled Study to Evaluate the Efficacy and Safety of YCANTH (VP-102) in Subjects With Common Warts (Verruca Vulgaris)
Lead sponsor
Verrica Pharmaceuticals Inc.
Phase
Phase 3
Overall status
Recruiting
Start date
December 17, 2025
Completion date
June 30, 2027
Enrollment
300 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

common warts, common warts (verruca vulgaris), human papilloma virus (hpv), warts